Patent SG-11201408002T-A (SG)
Title: Multi-parameter diabetes risk evaluations
Inventor: OTVOS JAMES D
IPC: G01N33/48
Filed: 2013-06-07
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/185014 A1 (51) International Patent Classification: G01N24/00 (2006.01) G01N33/48 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/044679 7 June 2013 (07.06.2013) English English (30) Priority Data: 61/657,315 8 June 2012 (08.06.2012) US 61/711,471 9 October 2012 (09.10.2012) US 61/739,305 19 December 2012 (19.12.2012) US 13/830,784 14 March 2013 (14.03.2013) US (71) Applicant: LIPOSCIENCE, INC. [US/US]; 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (US). (72) Inventors: OTVOS, James D.; 1117 Wellstone Circle, Apex, North Carolina 27502 (US). SHALAUROVA, Ir- ina Y.; 315 Ambermore Place, Cary, North Carolina 27519 (US). BENNETT, Dennis W.; 4242 North Morris Boulevard, Shorewood, Wisconsin 53211 (US). WOLAK- DINSMORE, Justyna E.; 2808 Mebane Lane, Durham, North Carolina 27703 (US). O'CONNELL, Thomas M.; 2 Aldershot Court, Chapel Hill, North Carolina 27517 (US). MERCIER, Kelly; 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (US). (74) Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, North Carolina 27627 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: MULTI-PARAMETER DIABETES RISK EVALUATIONS T-H o 00 FIG. 1A T-H o CJ (57) Abstract: Methods, systems and circuits evaluate subject's risk of developing type diabetes a 2 or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and plurality a of selected lipoprotein components of at least one biosample of the subject. WO 2013/185014 A11 lllll llllllll II llllll III lllll lllll III III III lllll lllll lllll lllll llll lllll llll lllllll llll llll u ls e ' — before the expiration of the time limit for amending the — with international search report (Art. 21(3)) claims and to be republished in the event of receipt of amendments (Rule 48.2(h))